Education, Teaching, and Quality Improvement |

The Use of a Noninvasive Respiratory Volume Monitor to Detect and Quantify Obstructive Sleep Apnea in Postoperative Patients FREE TO VIEW

Christopher Voscopoulos, MD; Diane Ladd, DNSc; Lisa Campana, PhD; Edward George, MD
Author and Funding Information

Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Chest. 2013;144(4_MeetingAbstracts):545A. doi:10.1378/chest.1702897
Text Size: A A A
Published online


SESSION TITLE: Improving Quality and Reducing Cost

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 29, 2013 at 02:45 PM - 04:15 PM

PURPOSE: Obstructive sleep apnea (OSA), while prevalent, remains underdiagnosed. This presents challenges after surgery, as OSA is associated with increased postoperative complications and often worsens with opioid administration. Previously, real-time identification of apneic events has been difficult using standard monitoring, with many events going unnoticed and untreated. A novel, non-invasive, Respiratory Volume Monitor (RVM) which provides respiratory volume traces and accurately reports Minute Ventilation (MV), Tidal Volume (TV) and Respiratory Rate (RR), has the potential to detect and quantify apneic events post-operatively.

METHODS: 92 patients undergoing elective orthopedic surgery were studied using an impedance-based RVM (ExSpiron, Respiratory Motion, Inc., Waltham, MA). Continuous RVM traces were obtained in the PACU and opioid administration (0.2mg PCA hydromorphone or 2.0 mg PRN morphine) recorded. Apneic episodes, defined as at least 10 seconds between successive breaths, were recorded and OSA was defined as more than 5 events per hour. MV, TV and RR were calculated from 30-second RVM trace segments.

RESULTS: OSA was observed in 19/ 92 patients (21%; mean age: 68.5, 53-86 years; mean BMI: 27.3, 15-38 kg/m2) in the PACU. An average of 37 ± 5.4 apneic events (13.1 ± 1.7 events/hr.) per patient were observed with an average duration of 14.9 ± 0.5, range 10-60 secs. During apneic breathing periods, MV was significantly lower compared to non-apneic periods (7.6 ± 0.9 L/min to 4.8 ± 0.5 L/min, -34 ± 3%, p<0.01). Importantly, 15/19 patients (79%) were not previously diagnosed with OSA. In 8/19 patients (42%), opioid administration initiated or exacerbated OSA. Analysis of age, gender, height, weight and BMI did not differentiate patients with apneic events from those without.

CONCLUSIONS: RVM traces can be used to detect apneic episodes in the PACU and quantify the reduction in MV caused by OSA. MV measurements may be the most useful way to quantitate the impact of OSA postoperatively. Traditional risk factors for OSA (age, male, BMI) were not predictive of post-operative OSA.

CLINICAL IMPLICATIONS: RVM provides non-invasive, real-time measurements that quantify respiration in patients with OSA and demonstrate the effect of opioids on this population. Since apneic episodes are associated with prolonged PACU stays, extra healthcare costs, and life-threatening post-surgical complications, the use of RVM to aid in decision-making regarding use of opioids may improve recognition and management of OSA in the PACU.

DISCLOSURE: Christopher Voscopoulos: Consultant fee, speaker bureau, advisory committee, etc.: Respiratory Motion, Inc. Diane Ladd: Employee: Respiratory Motion, Inc. Lisa Campana: Employee: Respiratory Motion, Inc. The following authors have nothing to disclose: Edward George

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543